scPharmaceuticals Inc. (SCPH): מחיר לרווח מתואם קצב צמיחה
The PEG growth potential ratio illustrates the valuation dynamics of scPharmaceuticals Inc. (SCPH), where 0.00 represents the latest metric level. The company is implementing the Furoscix system for home heart failure therapy to reduce hospital expenditures. Management is focusing on engagement with insurers to commercialize the product. The stability of medical technology supplies in the US is ensured by diversified chains and strategic warehouse reserves.
פילוחי מדדים ואנליטיקה של חברת scPharmaceuticals Inc. (SCPH)
The PEG ratio compares the market value of earnings to their expansion rate, where a value below one signals a fundamental undervaluation of the asset. The current peg_co metric at 0.00 reflects the balance between the share price and growth dynamics, which for scPharmaceuticals Inc. (SCPH) is supported by the expansion of its cardiology specialist staff while maintaining a stable core of R&D engineers.
